HIGHLIGHTS
- who: Thomas Du00f6rner from the Department Medicine/Rheumatology and Clinical Immunology, Charite (DRFZ), Chariteplatz, , Berlin, Germany have published the research work: Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial, in the Journal: (JOURNAL)
- what: The aim of this study was to evaluate the median change from baseline in conventional serologic biomarkers in subgroups and the overall population of baricitinib-treated patients with SLE and the SLE Responder Index-4 (SRI-4) response by normalization of anti-dsDNA.
- how: This may . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.